< Back to the team

A.Bordet

CFO

Experienced CFO in Health & Tech industries.

Aymeric Bordet, (CCA, SKEMA) is an experienced CFO (from Seed to 100M$ Series B) in Health & Tech  innovative companies / SMEs and General Secretary in Angelor (VC Seed).

Passionate about finance and innovation he wone the 2022 CFO trophy  DFCG Auvergne Rhône-Alpes.

Linkedin-in

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page